Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Revenues: |
| U.S. Medical | 225.3 | 206.7 | 167.4 | 130.1 | 117.4 | 105.9 | 101.0 | |
| International Medical | 45.5 | 39.3 | 37.5 | 28.7 | 22.8 | 21.4 | 16.9 | 84.0 |
| Other | | | | | | | | 30.8 |
| Total revenues | 270.8 | 246.0 | 204.9 | 158.8 | 140.3 | 127.3 | 117.9 | 114.8 |
| Revenue growth [+] | 10.1% | 20.0% | 29.0% | 13.2% | 10.2% | 7.9% | 2.7% | 10.4% |
| U.S. Medical | 9.0% | 23.5% | 28.6% | 10.8% | 10.9% | 4.9% | | |
| International Medical | 15.9% | 4.7% | 30.8% | 25.5% | 7.0% | 26.3% | -79.9% | |
| Cost of goods sold | 68.3 | 62.9 | 51.4 | 41.4 | 37.9 | 35.7 | 34.0 | 33.1 |
| Gross profit | 202.5 | 183.1 | 153.5 | 117.5 | 102.4 | 91.6 | 83.9 | 81.7 |
| Gross margin | 74.8% | 74.4% | 74.9% | 74.0% | 73.0% | 71.9% | 71.1% | 71.1% |
| Selling, general and administrative | 164.3 | 143.4 | 128.1 | 91.8 | 82.3 | 70.5 | 66.7 | 68.5 |
| Other operating expenses | 79.9 | 58.3 | 40.9 | 20.8 | 16.8 | 19.2 | 23.3 | 24.0 |
| EBITDA [+] | -14.3 | 8.0 | 1.3 | 15.5 | 13.1 | 11.8 | 3.9 | -0.9 |
| EBITDA growth | -278.0% | 522.7% | -91.7% | 17.9% | 11.0% | 207.2% | -509.3% | -119.0% |
| EBITDA margin | -5.3% | 3.3% | 0.6% | 9.8% | 9.4% | 9.3% | 3.3% | -0.8% |
| Depreciation | 15.2 | 13.3 | 10.5 | 9.7 | 9.9 | 10.0 | 9.7 | 9.9 |
| EBITA | -29.5 | -5.3 | -9.2 | 5.8 | 3.3 | 1.9 | -5.8 | -10.8 |
| EBITA margin | -10.9% | -2.1% | -4.5% | 3.6% | 2.3% | 1.5% | -4.9% | -9.4% |
| Amortization of intangibles | 12.2 | 13.3 | 6.3 | 0.9 | | | 0.3 | |
| EBIT [+] | -41.7 | -18.6 | -15.5 | 4.9 | 3.3 | 1.9 | -6.1 | -10.8 |
| EBIT growth | 124.7% | 19.6% | -417.9% | 49.9% | 73.1% | -130.8% | -43.5% | 345.4% |
| EBIT margin | -15.4% | -7.5% | -7.6% | 3.1% | 2.3% | 1.5% | -5.2% | -9.4% |
| Non-recurring items [+] | 1.9 | 32.0 | 21.4 | 4.5 | 0.3 | 0.6 | 0.9 | 1.2 |
| Asset impairment | | 2.5 | 4.1 | 4.5 | | | 0.9 | |
| Legal settlement | | | | | | 0.6 | | 1.2 |
| Interest expense, net [+] | 13.3 | 7.9 | 4.1 | 0.0 | 0.0 | -0.1 | -0.2 | -0.4 |
| Interest expense | 13.3 | 7.9 | 4.1 | 0.1 | 0.1 | 0.3 | 0.0 | |
| Interest income | | | | 0.0 | 0.0 | 0.1 | 0.2 | 0.4 |
| Other income (expense), net [+] | -0.4 | -0.4 | -0.2 | 0.1 | 0.1 | 0.0 | 0.0 | -1.7 |
| Gain (loss) on foreign currency transactions | -0.4 | -0.4 | -0.2 | 0.0 | 0.0 | -0.1 | 0.0 | |
| Change in value of contingent liability | | -25.8 | -1.1 | -5.2 | | | | |
| Other | -13.7 | -8.2 | -4.3 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
| Pre-tax income | -57.3 | -58.7 | -41.2 | 0.4 | 3.0 | 1.1 | -6.8 | -13.2 |
| Income taxes | 0.8 | 0.7 | -0.3 | 0.8 | 0.7 | 0.2 | 6.2 | 0.1 |
| Tax rate | | | 0.8% | 190.2% | 24.8% | 20.5% | | |
| Net income | -58.1 | -59.5 | -40.9 | -0.4 | 2.2 | 0.9 | -13.1 | -13.4 |
| Net margin | -21.5% | -24.2% | -20.0% | -0.2% | 1.6% | 0.7% | -11.1% | -11.6% |
| |
| Basic EPS [+] | ($1.35) | ($1.40) | ($0.98) | ($0.01) | $0.06 | $0.03 | ($0.39) | ($0.41) |
| Growth | -3.4% | 42.8% | 10227.9% | -114.7% | 142.3% | -106.8% | -4.0% | 230.8% |
| Diluted EPS [+] | ($1.35) | ($1.40) | ($0.98) | ($0.01) | $0.06 | $0.03 | ($0.39) | ($0.41) |
| Growth | -3.4% | 42.8% | 10227.9% | -115.3% | 139.3% | -106.6% | -4.0% | 230.8% |
| |
| Shares outstanding (basic) [+] | 42.9 | 42.4 | 41.7 | 38.9 | 34.4 | 33.5 | 33.1 | 32.5 |
| Growth | 1.2% | 1.8% | 7.0% | 13.3% | 2.7% | 1.1% | 1.7% | 2.2% |
| Shares outstanding (diluted) [+] | 42.9 | 42.4 | 41.7 | 38.9 | 35.8 | 34.4 | 33.1 | 32.5 |
| Growth | 1.2% | 1.8% | 7.0% | 8.9% | 4.1% | 3.9% | 1.7% | 2.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|